Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 6/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 2/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 4/20 | 0.36 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1769783 | 0.92 | DRD2 (0.42) | DRD2DHODHPRCPHTR7IDO1 | |
| Trifluoroacetic Acid SCHEMBL1769923 | 0.84 | DRD2 (0.39) | DRD2DHODHPRCPHTR7IDO1 | |
| Trifluoroacetic Acid SCHEMBL1769733 | 0.79 | DRD2 (0.45) | DRD2DHODHPRCPHTR7IDO1 | |
| Trifluoroacetic Acid SCHEMBL1769915 | 0.78 | F10 (0.38) | DHODHPRCPIDO1GPR6BCL2 | |
| SCHEMBL3822802 | 0.77 | DRD2 (0.45) | DRD2BCL2BAK1 | |
| Hydrochloric Acid SCHEMBL5123855 | 0.77 | DRD2 (0.44) | DRD2BCL2BAK1 | |
| Hydrochloric Acid SCHEMBL5128653 | 0.77 | DRD2 (0.44) | DRD2BCL2BAK1 | |
| Hydrochloric Acid SCHEMBL5131634 | 0.76 | DRD2 (0.45) | DRD2DHODHHTR7IDO1PDCD1LG2 | |
| SCHEMBL3815352 | 0.74 | DRD2 (0.42) | DRD2HTR7BCL2BAK1BCL2L1 | |
| Trifluoroacetic Acid SCHEMBL5127117 | 0.74 | DRD2 (0.41) | DRD2PRCPGPR6BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112104-A1 | TRICYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | LES LABORATOIRES SERVIER (FR) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112104-A1 | TRICYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | BAX, CASP3, BCL2 | DRD2 2186/4885DHODH 3783/4885PRCP 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.